within Pharmacolibrary.Drugs.V_Various.V08D_UltrasoundContrastMedia.V08DA01_PerflutrenHumanAlbuminMi;

model PerflutrenHumanAlbuminMi
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.9999999999999997e-06,
    adminDuration = 600,
    adminMass = 3 / 1000000,
    adminCount = 1,
    Vd = 0.0035,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PerflutrenHumanAlbuminMicrospheres</td></tr><tr><td>ATC code:</td><td>V08DA01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>3</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>180</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Perflutren, human albumin microspheres (marketed as Optison), is an injectable ultrasound contrast agent consisting of perflutren gas within human albumin microspheres. Its main use is to enhance echocardiographic imaging by creating better contrast in the blood pool. It is approved for clinical use for contrast enhancement in patients with suboptimal echocardiograms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers receiving a single intravenous injection.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V08DA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PerflutrenHumanAlbuminMi;
